Corvus CEO buys 6,932 shares in open market

Corvus Pharmaceuticals, Inc. President and CEO Dr. Richard A. Miller reported additional open-market purchases of the company’s common stock.

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. President and CEO Dr. Richard A. Miller reported additional open-market purchases of the company’s common stock. Through the Miller-Horning Family Trust, where he shares voting and investment power, the trust bought 1,932 shares at $12.01 per share and 5,000 shares at $12.05 per share on May 18, 2026, totaling 6,932 shares. After these transactions, he reports 1,136,707 shares held directly and 1,195,035 shares held indirectly through the trust.

Insider Trade Summary

Net Buyer: 6,932 shares

Net Buy 3 txns

Insider MILLER RICHARD A MD

Role President and CEO

Bought 6,932 shs ($83K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$12.05	$60K
Purchase	Common Stock	1,932	$12.01	$23K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,195,035 shares (Indirect, By Trust); Common Stock — 1,136,707 shares (Direct)

Footnotes (1)

1. F1. These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust.

Key Figures

Open-market purchase 1: 1,932 shares at $12.01 Open-market purchase 2: 5,000 shares at $12.05 Net insider buy: 6,932 shares +2 more

5 metrics

Open-market purchase 1 1,932 shares at $12.01 Common Stock bought on May 18, 2026 by trust

Open-market purchase 2 5,000 shares at $12.05 Common Stock bought on May 18, 2026 by trust

Net insider buy 6,932 shares Net buy across reported transactions

Direct holdings after transactions 1,136,707 shares Common Stock held directly by Richard A. Miller

Indirect holdings after transactions 1,193,103 shares Common Stock held indirectly via Miller-Horning Family Trust

Key Terms

open-market purchase, indirect ownership, By Trust, net-buy, +1 more

5 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"total_shares_following_transaction ... ownership_type": "indirect""

By Trust financial

"direct_or_indirect": "I", "nature_of_ownership": "By Trust""

net-buy financial

""netBuySellDirection": "net-buy""

voting, investment and dispositive power financial

"Dr. Miller has shared voting, investment and dispositive power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CRVS President and CEO Richard A. Miller report?

Dr. Richard A. Miller reported two open-market purchases of Corvus Pharmaceuticals (CRVS) common stock. A family trust associated with him bought 1,932 shares at $12.01 and 5,000 shares at $12.05 on May 18, 2026, totaling 6,932 shares.

At what prices did the CRVS insider purchases occur on May 18, 2026?

The insider purchases of Corvus Pharmaceuticals (CRVS) stock occurred at prices of $12.01 and $12.05 per share. These were open-market transactions by a family trust associated with CEO Richard A. Miller, as disclosed in the Form 4 filing.

How many Corvus Pharmaceuticals (CRVS) shares does Richard A. Miller now hold?

Following the reported transactions, Richard A. Miller holds 1,136,707 Corvus Pharmaceuticals (CRVS) shares directly. He also reports 1,193,103 shares held indirectly through the Miller-Horning Family Trust, where he shares voting and investment power over the trust’s holdings.

Were the recent CRVS insider share purchases made directly or through an entity?

The recent Corvus Pharmaceuticals (CRVS) insider share purchases were made indirectly through the Miller-Horning Family Trust. Dr. Richard A. Miller and Sandra J. Horning serve as trustees and share voting, investment, and dispositive power over the trust’s CRVS shares.

What is the total size of the net insider buy reported for CRVS?

The Form 4 for Corvus Pharmaceuticals (CRVS) shows a net insider buy of 6,932 common shares. This reflects two open-market purchases by the Miller-Horning Family Trust on May 18, 2026, with no reported sales or derivative exercises in the same filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLER RICHARD A MD

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		P		5,000	A	$12.05	1,193,103	I	By Trust(1)
Common Stock	05/18/2026		P		1,932	A	$12.01	1,195,035	I	By Trust(1)
Common Stock								1,136,707	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust.

	/s/ Leiv Lea, as Attorney-in-Fact for Richard A. Miller	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)